Statement of Ownership (sc 13g)
07 Aprile 2022 - 12:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
Lixte
Biotechnology Holdings, Inc.
(Name
of Issuer)
Common
Stock, $0.0001 par value per share
(Title
of Class of Securities)
539319
202
(CUSIP
Number)
December
17, 2021
(Date
of Event Which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
|
☐ |
Rule
13d-1(b) |
|
|
|
|
☒ |
Rule
13d-1(c) |
|
|
|
|
☐ |
Rule
13d-1(d) |
*The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover
page.
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
not be subject to all other provisions of the Act (however, see the Notes).
CUSIP
NO. 539319 10 3 |
|
Page
2 of 5 Pages |
|
1. |
NAMES
OF REPORTING PERSONS.
Glenn
Krinsky |
|
|
|
|
2.
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
☐
(b)
☒ |
|
|
|
|
3. |
SEC
USE ONLY |
|
|
|
|
|
|
|
4. |
CITIZENSHIP
OR PLACE OF ORGANIZATION
United
States
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH |
5. |
SOLE
VOTING POWER |
1,474,998 |
|
|
|
6. |
SHARED
VOTING POWER |
|
|
|
|
7. |
SOLE
DISPOSITIVE POWER |
1,474,998 |
|
|
|
8. |
SHARED
DISPOSITIVE POWER |
|
|
|
|
|
9. |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON.
1,474,998(1) |
|
|
|
|
|
|
|
10. |
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
☐ |
|
|
|
|
|
|
|
|
|
11. |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
10.73%
(2) |
|
|
|
|
12. |
TYPE
OF REPORTING PERSON
IN
|
|
(1) |
Consists
of 1,333,333 shares owned of record by the John and Barbara Kovach 2015 Trust of which the Reporting person is the sole Trustee and
has voting, dispositive and investment power |
|
(2) |
Based
on 13,746,593 shares of Common Stock, outstanding as of March 11, 2022. |
CUSIP
NO. 539319 10 3 |
|
Page
3 of 5 Pages |
Explanatory
Note: On December 17, 2021, the Reporting Person was appointed as successor Trustee of the John and Barbara 2015 Trust.
Item 1(a). |
Name of Issuer. |
The
name of the issuer is Lixte Biotechnology Holdings, Inc. (the “Issuer”).
Item 1(b). |
Address of Issuer’s Principal Executive Offices. |
The
address of the Issuer’s principal executive office is 680 East Colorado Boulevard, Suite 180, Pasadena CA 91101.
Item 2(a). |
Name of Person Filing. |
Glenn
Krinsky
Item 2(b). |
Address of Principal Business Office, or, if None,
Residence. |
680
East Colorado Boulevard, Suite 180, Pasadena CA 91101
United
States citizen.
Item 2(d). |
Title of Class of Securities. |
The
title of the class of securities to which this statement relates is the Common stock, $0.0001 par value per share.
The
CUSIP number is 539319-202.
Item 3. |
If This Statement is Filed Pursuant to Rule 13d-1(b) or 13d-2(b), Check
Whether the Person Filing is a: |
(a) |
☐ |
Broker
or dealer registered under Section 15 of the Act |
|
|
|
(b) |
☐ |
Bank
as defined in Section 3(a)(6) of the Act |
|
|
|
(c) |
☐ |
Insurance
Company as defined in Section 3(a)(19) of the Act |
|
|
|
(d) |
☐ |
Investment
Company registered under Section 8 of the Investment Company Act of 1940 |
|
|
|
(e) |
☐ |
Investment
Adviser registered under section 203 of the Investment Advisers Act of 1940 |
|
|
|
(f) |
☐ |
Employee
Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment
Fund; see Rule 13d-1(b)(1)(ii)(F) |
|
|
|
(g) |
☐ |
Parent
Holding Company, in accordance with Rule 13d-1(b)(1)(ii)(G) (Note: See Item 7) |
|
|
|
(h) |
☐ |
Group,
in accordance with Rule 13d-1(b)(1)(ii)(H). |
CUSIP
NO. 539319 10 3 |
|
Page
4 of 5 Pages |
The
information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover pages and is incorporated herein by reference.
Item 5. |
Ownership of Five Percent or Less of a Class. |
Not
Applicable.
Item 6. |
Ownership of More than Five Percent on Behalf of Another Person. |
Not
Applicable.
Item 7. |
Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company. |
Not
Applicable.
Item 8. |
Identification and Classification of Members of the Group. |
Not
Applicable.
Item 9. |
Notice of Dissolution of Group. |
Not
Applicable.
By
signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired
and are not held in connection with or as a participant in any transaction having that purpose or effect.
CUSIP
NO. 539319 10 3 |
|
Page
5 of 5 Pages |
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
|
Dated:
April 06, 2022 |
|
|
|
/s/
GLENN KRINSKY |
|
Glenn
Krinsky |
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Lug 2023 a Lug 2024